Diverticular Diseases: Clinical Trials

14 trials for Diverticular Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 3 terminated, 3 unknown. 14 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 314Completed 8, Terminated 3, Unknown 3
Phase 24Completed 2, Terminated 1, Unknown 1

Follow Diverticular Diseases: new trials by email Literature Review of Diverticular Diseases trials Research Report on Diverticular Diseases

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.
Rifaximin delayed released 400mg Tablet, Placebo - Diverticulitis
Phase 2 / Phase 3TerminatedAlfasigma S.p.A.1932018-07-022021-10-20
The Role of Indocyanine Green (ICG) Fluorescence Imaging on Anastomotic Leak in Robotic Colorectal Surgery
Near-infrared ICG fluorescence imaging, Traditional bowel anastomosis, FireFly™ - Colon Neoplasms, Rectal Neoplasms
Phase 2 / Phase 3UnknownAcibadem University1022015-11-012015-11-24
Effect of a Probiotic on Diverticular Symptoms
Probiotic - Diverticular Disease
Phase 3CompletedKing's College Hospital NHS Trust1432013-04-012016-06-09
Informativeness to Digital Rectal Examination
lateral decubitus, supine decubitus - Colon Cancer, Upper Rectum Cancer
Phase 3CompletedCentre Hospitalier Universitaire, Amiens3202012-11-012025-09-19
Laparoscopic Peritoneal Lavage or Resection for Generalised Peritonitis for Perforated Diverticulitis
Laparoscopic lavage and drainage, Sigmoidectomy with primary anastomosis, Sigmoidectomy with end-colostomy - Perforated Diverticulitis
Phase 3UnknownAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)2832010-04-012014-03-21
Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis
Mesalazine, Placebo - Diverticulitis
Phase 3TerminatedDr. Falk Pharma GmbH3302010-01-012017-07-21
Role Of Lactobacillus Reuteri DSM 17938 In The Non-Complicated Diverticular Disease
Lactobacillus Reuterii, placebo - Diverticulosis, Diverticulitis
Phase 3UnknownCasa Sollievo della Sofferenza IRCCS1602009-02-012011-06-28
Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis
Mesalazine, Placebo - Diverticulitis
Phase 3TerminatedDr. Falk Pharma GmbH3452008-01-012017-07-24
Prevention of Recurrence of Diverticulitis
SPD476, MMX™ mesalazine, 1.2g extended release tablet, SPD476, MMX™ mesalazine, 2.4g extended release tablet, SPD476, MMX™ mesalazine, 4.8g extended release tablet - Diverticulitis
Phase 3CompletedShire5922007-12-062021-06-11
Prevention of Recurrence of Diverticulitis
SPD476 (1.2g), SPD476 (2.4 g), SPD476 (4.8 g) - Diverticulitis
Phase 3CompletedShire5902007-11-282021-06-14
An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy
Hextend, Lactated Ringers - Crohn's Disease, Ulcerative Colitis
Phase 3CompletedCorewell Health West692007-05-012009-10-21
Hartmann's Versus Primary Anastomosis in Left-sided Colon Perforation
Hartmann's operation, Primary anastomosis - Surgery, Diverticulitis
Phase 2 / Phase 3CompletedUniversity of Zurich622006-05-012012-05-28
Evaluation of Efficacy of Mesalamine in the Long-term Prevention of Diverticulitis Flares
mesalamine, placebo - Diverticular Disease
Phase 3CompletedSOFAR S.p.A.1052005-10-012013-09-18
Hartmann vs R/A in Peritonitis by Perforated Diverticulitis
Primary sigmoid resection with end colostomy (Hartmann), Primary sigmoid resection and immediate anastomosis with diverting stoma (PRA) - Peritonitis Caused by Perforated Left-sided Colon Diverticulitis
Phase 2 / Phase 3CompletedEnte Ospedaliero Ospedali Galliera1002000-01-012010-11-15

Narrower conditions

Diverticulitis (12)  ·  Colonic Neoplasms (3)  ·  Rectal Neoplasms (3)  ·  Diverticulum (2)  ·  Anastomotic Leak (1)  ·  Colitis, Ulcerative (1)  ·  Colonic Polyps (1)  ·  Colorectal Neoplasms (1)  ·  Crohn Disease (1)  ·  Gastrointestinal Hemorrhage (1)  ·  Hernia (1)  ·  Inflammatory Bowel Diseases (1)  ·  Intestinal Perforation (1)  ·  Neoplasms (1)

Broader conditions

Digestive System Diseases (14)  ·  Gastroenteritis (14)  ·  Gastrointestinal Diseases (14)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Intestinal Diseases (4)  ·  Pathological Conditions, Anatomical (4)  ·  Colonic Diseases (3)  ·  Digestive System Neoplasms (3)  ·  Gastrointestinal Neoplasms (3)  ·  Intestinal Neoplasms (3)  ·  Neoplasms (3)  ·  Neoplasms by Site (3)  ·  Pathologic Processes (3)  ·  Rectal Diseases (3)

Interventions

Mesalamine (5)  ·  Colectomy (1)  ·  Drainage (1)  ·  Hydroxyethyl Starch Derivatives (1)  ·  Indocyanine Green (1)  ·  Probiotics (1)  ·  Ringer's Lactate (1)  ·  Tablets (1)

Sponsors

Dr. Falk Pharma GmbH (2)  ·  Shire (2)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)  ·  Acibadem University (1)  ·  Alfasigma S.p.A. (1)  ·  Casa Sollievo della Sofferenza IRCCS (1)  ·  Centre Hospitalier Universitaire, Amiens (1)  ·  Corewell Health West (1)  ·  Ente Ospedaliero Ospedali Galliera (1)  ·  King's College Hospital NHS Trust (1)  ·  SOFAR S.p.A. (1)  ·  University of Zurich (1)

Countries

Italy (5)  ·  United States (4)  ·  France (3)  ·  Germany (3)  ·  Netherlands (3)  ·  United Kingdom (3)  ·  Spain (2)  ·  Argentina (1)  ·  Australia (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  Colombia (1)  ·  Finland (1)  ·  Hungary (1)

Top investigators

Wolfgang Kruis, Professor (2)  ·  Alberto Serventi (1)  ·  Anthony Senagore, MD (1)  ·  Bilgi Baca, MD,Prof.Dr. (1)  ·  Gian Andrea Binda (1)  ·  Ingvar Bjarnason, MD, MSc (1)  ·  J.F. Lange, Professor (1)  ·  Roberto Bergamaschi, MD (1)  ·  Savvas Papagrigoriadis, MD, MSc (1)  ·  Stefan Breitenstein, MD (1)  ·  W.A. Bemelman, Professor (1)

Results publications

PMID 25038431, PMID 28543263, PMID 28707787, PMID 28707796, PMID 23095627, PMID 23754545, PMID 24566744, PMID 25245464, PMID 25451666, PMID 26209030, PMID 31178342, PMID 35606544

NIH funding

2009 (1), 2017 (1)